Top Line Results: No Cardiovascular Benefits Found For Saxagliptin

Top line results of a large phase 4 study with saxagliptin (Onglyza, Bristol-Myers Squibb and AstraZeneca) demonstrate that the drug is safe but has no cardiovascular benefits. AstraZeneca and Bristol-Myers Squibb today announced the top line results for the SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza®. The full results are scheduled to presented at the  annual meeting of the European Society of Cardiology in Amsterdam on September 2 by Deepak Bhatt. … Click here to read the full story on Forbes.  
Source: CardioBrief - Category: Cardiology Authors: Tags: Policy & Ethics Prevention, Epidemiology & Outcomes AstraZeneca Bristol Myers Squibb Dipeptidyl peptidase-4 inhibitor European Society of Cardiology food and drug administration Onglyza Saxagliptin Source Type: blogs